Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy

Leempoel, Jonathan;Ruyssen, Antoine;Kessler, Roger;Van Pesch, Vincent;Gille, Michel
(2020) Acta Neurologica Belgica — Vol. 120, n° 2, p. 451-452 (2020)

Files

RuyssenetalANB.pdf
  • Open Access
  • Adobe PDF
  • 485.09 KB
Download

Details

Authors
Abstract
(en) Immune checkpoint inhibitors (ICPIs) are efective and promising in the treatment of metastatic cancers. They include anti-programmed cell death 1 (PD-1), anti-PD ligand 1 (PDL1), and anti-cytotoxic lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies (mAbs). However, ICPI-induced T-cell activation can also cause autoimmune adverse events in many host organs, including the nervous system [1, 2]. We report on a patient who developed an antiMa2/Ta rhombencephalitis associated upon treatment of a metastatic non-small cell lung cancer responsive to pembrolizumab, an anti-PD-1 mAb. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Leempoel, J., Ruyssen, A., Kessler, R., Van Pesch, V., & Gille, M. (2020). Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy. Acta Neurologica Belgica, 120(2), 451-452. https://doi.org/10.1007/s13760-019-01179-3 (Original work published 2020)